DYVOX Dynavox Group AB (publ)
Dynavox Group AB (publ), through its subsidiaries, engages in the development and sale of assistive technology products for customers with communication disabilities. The company offers custom designed augmentative and alternative communication (AAC) solutions that enable people with disabilities, such as cerebral palsy, ALS, autism, and spinal cord injury, to communicate on their own. Its communication solutions include language, software, hardware, funding, support, and training. The company operates in Sweden, Norway, Denmark, Belgium, the United States, Germany, France, China, the United Kingdom, Ireland, Australia, and New Zealand. The company was formerly known as Tobii Dynavox AB (publ) and changed its name to Dynavox Group AB (publ) in July 2024. Dynavox Group AB (publ) was incorporated in 2012 and is headquartered in Stockholm, Sweden.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Dynavox Group (STO: DYVOX)
›
Dynavox Group (STO: DYVOX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 1,107 employees.
The shares were at 75.90 SEK on 19 November 2026, down 17.9% over 52 weeks. Its 52-week range is 57.20 SEK to 105.50 SEK: the price is 28.1% below the high and 32.7% above the low.
At a market capitalisation of 8.05B SEK, it trades at 29.6 times trailing earnings and 36.1 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 40% for DYVOX. It pays a dividend yielding 0.67% (it pays out 19% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Dynavox Group reports return on equity of 27.5%, an operating margin of 16.3% and revenue up 13.0% year over year.
Its debt exceeds its cash by 828.00M SEK, a debt-to-equity ratio of 1.83. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 110.75 SEK is 45.9% above the current price. The next earnings report is expected on 4 February 2027.